Epstein-Barr Virus Infections Clinical Trials

7 recruiting

Epstein-Barr Virus Infections Trials at a Glance

7 actively recruiting trials for epstein-barr virus infections are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in New York, Columbus, and Bethesda. Lead sponsors running epstein-barr virus infections studies include Jessie L. Alexander, Marengo Therapeutics, Inc., and Columbia University.

Browse epstein-barr virus infections trials by phase

Treatments under study

About Epstein-Barr Virus Infections Clinical Trials

Looking for clinical trials for Epstein-Barr Virus Infections? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Epstein-Barr Virus Infections trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Epstein-Barr Virus Infections clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

LymphomaEpstein-Barr Virus InfectionsLymphoproliferative Disorder+1 more
National Cancer Institute (NCI)40 enrolled1 locationNCT03258567
Recruiting
Phase 1Phase 2

Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity

Epstein-Barr Virus InfectionsCytomegalovirus InfectionsAdenovirus
Jessie L. Alexander25 enrolled3 locationsNCT06909110
Recruiting
Phase 2

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

Epstein-Barr Virus InfectionsPrimary Immune Deficiency Disorder
New York Medical College20 enrolled8 locationsNCT03266653
Recruiting
Phase 1Phase 2

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Advanced Solid TumorsCarcinomaNeoplasms+9 more
Marengo Therapeutics, Inc.365 enrolled32 locationsNCT05592626
Recruiting
Phase 1

R-MVST Cells for Treatment of Viral Infections

Epstein-Barr Virus InfectionsCytomegalovirus InfectionsBK Virus Infection+1 more
Columbia University36 enrolled1 locationNCT05183490
Recruiting
Phase 4

Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft

Epstein-Barr Virus Infections
University Hospital, Strasbourg, France120 enrolled1 locationNCT04989491
Recruiting

Evaluation of CMV/EBV-CMI in Haploid HSCT

Epstein-Barr Virus InfectionsHematopoietic Stem Cell TransplantationCytomegalovirus Infections
The First Affiliated Hospital of Soochow University60 enrolled1 locationNCT06554197